Retrophin (RTRX): DUET Data At ASN Could Preview FDA - BMO

November 4, 2016 7:29 AM EDT
Get Alerts RTRx Hot Sheet
Price: $19.53 --0%

Rating Summary:
    5 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 8 | New: 3
Trade RTRx Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

BMO Capital analyst, Do Kim, reiterated his Outperform rating on shares of Retrophin (NASDAQ: RTRx) ahead of the detailed DUET data at the American Society of Nephrology (ASN) meeting on 11/19/2016. The analyst believes this could provide additional clarity on accelerated filing, if the key question about the appropriate commercial dose is addressed.

The analyst believes an unambiguous dose-response would increase the likelihood of positive FDA feedback (Jan 2017) and could drive significant upside to shares. No change to the $40 price target.

For an analyst ratings summary and ratings history on Retrophin click here. For more ratings news on Retrophin click here.

Shares of Retrophin closed at $18.60 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Related Entities

BMO Capital

Add Your Comment